LakeShore Biopharma Co Ltd
NASDAQCM:LSB
China / Healthcare / Biotechnology
LSB News
Welcome to Your News Upgrade
Be the First to Know and Act on Market Moving News.
LakeShore Biopharma Announces the Official Launch of a Novel Packaging Solution for YSJA™ Rabies Vaccine (Vero Cell)
Revolutionizing Vaccination Safety with Needle-Free Reconstitution Technology BEIJING, April 23, 2025 /PRNewswire/ -- On April 18, 2025, LakeShore Biopharma Co., Ltd. (Nasdaq:...
LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance
Achieved total revenue of RMB 371.9 million, reflecting a growth of 36.2% YoYAchieved gross profit of RMB 307.3 million, a growth of 39.1% YoYGross margin increased to 82.6% from...
LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China
BEIJING, Dec. 12, 2024 (GLOBE NEWSWIRE) -- LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) (LakeShore Biopharma or the Company), a leading global biopharmaceutical company focused on...
LakeShore Biopharma Initiates Biologics License Application of PIKA Rabies Vaccine to the Drug Regulatory Authority of Pakistan
GAITHERSBURG, Md., Nov. 07, 2024 (GLOBE NEWSWIRE) -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) (LakeShore Biopharma or the Company), a global leader in the discovery,...
LakeShore Biopharma regains Nasdaq compliance
GAITHERSBURG, Md. - LakeShore Biopharma Co., Ltd (NASDAQ:LSB), a biopharmaceutical company, announced today that it has regained compliance with the Nasdaq's minimum bid price...
LakeShore Biopharma Regains Nasdaq Compliance
LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and...
LakeShore Biopharma to test simplified rabies vaccine regimen
GATITHERSBURG, Md. - LakeShore Biopharma Co., Ltd (NASDAQ:LSB), a biopharmaceutical company, has received approval from China's National Medical Products Administration to conduct...
LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine
LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and...
LakeShore Biopharma projects steady growth for FY2025
GAITHERSBURG, Md. - LakeShore Biopharma Co., Ltd (NASDAQ:LSB), a global biopharmaceutical company, announced today its financial guidance for the first half and reaffirmed its...
LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance
LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and...